Impact of Epidermal Growth Factor Receptor Mutation on Clinical Outcomes of Nintedanib Plus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer from the Korean Named Patient Program.

CONCLUSIONS: Our data indicated that nintedanib-docetaxel combination could be considered to be effective treatment in EGFR TKI-resistant EGFR mutant NSCLC.
PMID: 30368503 [PubMed - as supplied by publisher]

Source: Oncology - October 26, 2018 Category: Cancer & Oncology Authors: Hong SH, An HJ, Kim K, Lee SS, Lee YG, Yuh YJ, Park IC, Chae YS, Jang TW, Kang JH Tags: Oncology Source Type: research